Tradestie Institutional Equity Comparison Engine

RLAY vs LCTX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LCTX Overall Edge

LCTX Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lineage Cell Therapeutics, Inc. (LCTX) driven by superior Valuation, Growth & Margin while RLAY counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, RLAY trades at N/M Forward P/E with -3094.6% operating margin (-48.3% YoY revenue) versus LCTX at 30.7x Forward P/E and -280.3% operating margin (-61.0% YoY). In options structure, RLAY sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro) against LCTX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LCTX
RLAY N/M vs LCTX 30.7x Fwd P/E
Growth & Margin Winner LCTX
Op Margin -3094.6% vs -280.3% ยท YoY -48.3% vs -61.0%
Momentum & Technical Winner RLAY
1Y +144.4% vs -53.7% ยท 52W Pos 64% vs 4%
Options & Structure Winner RLAY
CONSOLIDATION (6th %ile IV) vs BREAKDOWN (100th %ile IV)
RLAY NASDAQ
Relay Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$15.91
-3.63% 1D
Market Cap $3.6B
1M Return -13.58%
1Y Return +144.39%
Forward P/E N/M
Unified AI Score
47.3 / 100 HOLD
Tech 35.0 Fund 58.0 Flow 69.0 Mom 60.0
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap $212.1M
1M Return -13.82%
1Y Return -53.67%
Forward P/E 30.7x
Unified AI Score
58.9 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 65.0 Mom 45.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RLAY +144.39% LCTX -53.67% Spread: +198.06 pp (RLAY Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period RLAY Revenue LCTX Revenue RLAY Op. Margin LCTX Op. Margin Margin Edge
FY2018 N/A $0M N/A -837.9% LCTX
FY2019 N/A $0M N/A -1106.0% LCTX
FY2020 $80M $0M -67.5% -1448.4% RLAY
FY2021 $0M $0M -12040.2% -1133.6% LCTX
FY2022 $0M $10M -21670.9% -153.2% LCTX
FY2023 $30M $10M -1460.1% -276.5% LCTX
FY2024 $10M $10M -3722.1% -226.1% LCTX
FY2025 $20M $10M -1971.6% -251.6% LCTX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RLAY (4) vs LCTX (6)
Institutional Metric RLAY LCTX Criterion Row Winner
Market Capitalization Scale $3.6B $212.1M Larger Scale RLAY
Trailing P/E Ratio Valuation N/M 30.7x Lower Multiple LCTX
Forward P/E Ratio Valuation N/M 30.7x Lower Multiple LCTX
Revenue Growth (YoY) Growth -48.3% -61.0% Higher Growth RLAY
Operating Margin (TTM) Profitability -3094.6% -280.3% Higher Margin LCTX
Net Profit Margin Profitability 0.0% 16.2% Higher Margin LCTX
Return on Equity (ROE) Capital Efficiency -41.2% 4.3% Higher ROE LCTX
52-Week Range Position Momentum 64% ($6โ€“$21) 4% ($1โ€“$2) Stronger Trend RLAY
Beta / 30D Volatility Risk Regime 1.74ฮฒ ยท 74% Vol 1.36ฮฒ ยท 79% Vol Lower Realized Risk RLAY
Unified Institutional Score Composite Signal 47.3 / 100 (HOLD) 58.9 / 100 (HOLD) Higher Composite LCTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RLAY vs LCTX Buy Guide
RLAY CONSOLIDATION
104d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live RLAY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LCTX BREAKDOWN
6d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live LCTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RLAY nor LCTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.